Cleveland Biolabs Inc.

306 articles about Cleveland Biolabs Inc.

• Cytocom Inc. Provides Update on Completed Merger with Cleveland BioLabs

  8/5/2021

  Cytocom Inc. today provided shareholders with an update regarding its recent merger with Cleveland BioLabs.

• Cleveland BioLabs, Inc. and Cytocom Inc. Announce Call to Discuss Stockholder Meeting Vote Results and Proposed Merger

  7/6/2021

  Cleveland BioLabs, Inc. today announced that the Company and Cytocom Inc.will host an investor call and live webcast on Wednesday, July 7 at 8:30 a.m. ET.

• Cleveland BioLabs, Inc. and Cytocom Announce Registration Statement and Proxy Statement for Previously Announced Merger Declared Effective by SEC

  6/17/2021

  Cleveland BioLabs, Inc. (NASDAQ: CBLI), an innovative biopharmaceutical company developing novel approaches to activate the immune system, announced that its registration statement on SEC Form S-4 (the "Registration Statement") filed with U.S. Securities and Exchange Commission (the "SEC") in connection with its previously announced merger with Cytocom Inc.

• Genome Protection Announces Publication of the Next Generation Deimmunized TLR5 Agonist, GP532

  4/14/2021

  Genome Protection, Inc. (GPI), a joint venture between Cleveland BioLabs, Inc. (NASDAQ:CBLI) and Everon BioSciences, LLC, an innovative biopharmaceutical company focused on developing medical interventions to prevent and treat aging and age-related diseases, announces a publication

• Cleveland BioLabs, Inc. Announces Closing of $14 Million Registered Direct Offering of Common Stock

  2/23/2021

  Cleveland BioLabs, Inc., announced that it has closed its previously announced registered direct offering for the issuance and sale of 2,000,000 shares of its common stock at a purchase price of $7.00 per share.

• Cleveland BioLabs, Inc. Announces $14 Million Registered Direct Offering of Common Stock

  2/19/2021

  Cleveland BioLabs, Inc. (NASDAQ:CBLI), today announced that it has entered into definitive agreements with certain healthcare-focused and institutional investors for the issuance and sale of 2,000,000 shares of its common stock at a purchase price of $7.00 per share in a registered direct offering.

• Cleveland BioLabs, Inc. Files Registration Statement on Form S-4 for Proposed Merger with Cytocom Inc.

  2/17/2021

  Combined public entity to develop and commercialize next-generation immune therapies that address unmet needs in oncology, infectious disease, inflammation and auto-immune-mediated conditions

• Cleveland BioLabs, Inc. Files Registration Statement for Proposed Merger with Cytocom Inc.

  2/17/2021

  Combined public entity to develop and commercialize next-generation immune therapies that address unmet needs in oncology, infectious disease, inflammation and auto-immune-mediated conditions FORT COLLINS, CO and BUFFALO, NY / ACCESSWIRE / February 17, 2021 / Cleveland BioLabs, Inc. (NASDAQ:CBLI), an innovative biopharmaceutical company developing novel approaches to activate the immune system, filed a registration statement on Form S-4 (the "Registration Statement") with the U

• Immune Therapeutics, Inc. Announces Signing of Definitive Merger Agreement Between Cytocom and Cleveland BioLabs Merger

  10/20/2020

  Cytocom, Inc. (Cytocom), a leading biopharmaceutical company in the area of immune-modulation, and Cleveland BioLabs, Inc., an innovative biopharmaceutical company developing novel approaches to activate the immune system, today announced that they have entered into a definitive merger agreement to combine their businesses in an all-stock transaction.  Cytocom shareholders will have a majority position in the newly combined entity, which the

• Cleveland BioLabs Closes $3.175 Million Registered Direct Offering Priced At-The-Market Under NASDAQ Rules

  6/5/2020

  Cleveland BioLabs, Inc., announced the closing of its previously announced registered direct offering to several institutional and accredited investors of an aggregate of 1,515,878 shares of its common stock, at a purchase price of $2.0945 per share.

• Cleveland BioLabs Announces $3.175 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

  6/2/2020

  Cleveland BioLabs, Inc., announced that it has entered into definitive agreements with several institutional and accredited investors for the issuance and sale of an aggregate of 1,515,878 shares of its common stock, at a purchase price of $2.0945 per share, in a registered direct offering priced at-the-market under Nasdaq rules.

• Cleveland BioLabs Reports Third Quarter 2017 Financial Results and Development Progress

  11/14/2017

  Cleveland BioLabs reported a net loss of $(1.3) million, excluding minority interests, for the third quarter of 2017, or $(0.11) per share, compared to a net gain, excluding minority interests, of $1.1 million, or $0.10 per share, for the same period in 2016.

• Cleveland Biolabs Inc. Reports Second Quarter 2017 Financial Results And Development Progress

  8/14/2017

• Cleveland Biolabs Inc. Reports First Quarter 2017 Financial Results And Development Progress

  5/16/2017

• Cleveland Biolabs Inc. Announces EMA Positive Opinion Regarding The Entolimod Pediatric Investigation Plan

  4/17/2017

• Cleveland Biolabs Inc. Announces Commencement Of In Vivo Biocomparability Study

  4/17/2017

• Cleveland Biolabs Inc. Reports 2016 Financial Results And Development Progress

  2/23/2017

• Cleveland Biolabs Inc. Reports Third Quarter 2016 Financial Results And Development Progress

  11/15/2016

• Cleveland Biolabs Inc. Announces A $1.1 Million Cost Realignment With The Department Of Defense

  10/12/2016

• Cleveland Biolabs Inc. Reports Second Quarter 2016 Financial Results And Development Progress

  8/16/2016